The Western Australian Future Health Research and Innovation Fund has awarded a A$499,241 Innovation Seed Fund grant to Virex Pharma for development of Glyxine, an inhaled antiviral nanoemulsion, for the treatment of respiratory syncytial virus. According to Virex, the grant will go toward testing of Glyxine in epithelial cells and in animal models of RSV at Wal-yan Respiratory Research Center in Perth.
University of Western Australia Associate Professor Anthony Kicic commented, “The active pharmaceutical ingredient used in Glyxine has long been used for intravenous treatment of viral hepatitis infections, and it is abundantly produced for commercial purposes, is readily available, and is cheap – so it offers a convenient treatment option. At the Wal-yan Centre we are well placed to carry out rigorous scientific research to further test the safety, effectiveness and tolerability of Glyxine and to advance its development.”
Read the Virex Pharma press release.
